脂质体阿霉素治疗晚期复发性铂耐药型卵巢癌的近期疗效及安全性

Short-term efficacy and safety of liposome doxorubicin in the treatment of advanced recurrent platinum-resistant ovarian cancer

目的探讨脂质体阿霉素治疗晚期复发性铂耐药型卵巢癌患者的近期疗效及安全性。方法选取2019年1月至2021年1月本院收治的106例晚期复发性铂耐药型卵巢癌患者作为研究对象,按照随机数字表法分为观察组与对照组,每组53例。对照组给予依托泊苷治疗,观察组给予脂质体阿霉素治疗,比较两组近期疗效、肿瘤相关标志物水平及不良反应发生情况。结果两组疾病控制率、客观缓解率比较差异无统计学意义。治疗后,两组糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、人附睾蛋白4(HE4)水平均低于治疗前,差异有统计学意义(P<0.05),但两组间比较差异无统计学意义。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论脂质体阿霉素治疗晚期复发性铂耐药型卵巢癌患者近期疗效显著,有利于降低肿瘤相关标志物水平,且与依托泊苷相比,脂质体阿霉素的不良反应较少。

Objective To investigate the short-term efficacy and safety of liposome doxorubicin in the treatment of patients with advanced recurrent platinum-resistant ovarian cancer.Methods 106 patients with advanced recurrent platinum-resistant ovarian cancer admitted to our hospital from January 2019 to January 2021 were selected as the research subjects,and they were divided into the observation group and the control group according to the random number table method,with 53 cases in each group.The control group was given etoposide treatment,and the observation group was given liposome doxorubicin treatment,the short-term efficacy,levels of tumor-related markers and adverse reactions were compared between the two groups.Results There was no significant difference in disease control rate and objective remission rate between the two groups.After treatment,the levels of carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)and human epididymal protein 4(HE4)of the two groups were significantly lower than those before treatment,and the differences were statistically significant(P<0.05),but there was no significant difference between the two groups.The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Liposome doxorubicin has significant short-term efficacy in the treatment of advanced recurrent platinum-resistant ovarian cancer,which is beneficial to reduce the level of tumor-related markers,and has fewer adverse reactions compared with etoposide.